About: Drug repurposing of anti-infective clinical drugs: Discovery of two potential anti-cytokine storm agents

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Drug repurposing of anti-infective clinical drugs: Discovery of two potential anti-cytokine storm agents Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Drug repurposing of anti-infective clinical drugs: Discovery of two potential anti-cytokine storm agents
Creator	Su, Li Chen, Da-Gui Kong, De-Pei Tu, Ye Wang, Zhi-Bin Zhang, Chen-Xi Zhang, Wan-Nian Zhuang, Chun-Lin
Source	Elsevier; Medline; PMC
abstract	Coronavirus Disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2) has been widely spread in the world with a high mortality. Cytokine storm syndrome (CSS) and acute lung injury caused by SARS-CoV-2 infection severely threaten the patients. With the purpose to find effective and low-toxic drugs to mitigate CSS, entecavir and imipenem were identified to reduce TNF-α using a LPS-induced macrophage model from the anti-infective drug library. Entecavir and imipenem efficiently suppressed the release of inflammatory cytokines by partly intervention of NF-κB activity. The acute lung injury was also alleviated and the survival time was prolonged in mice. In addition, entecavir and imipenem inhibited the release of TNF-α and IL-10 in human peripheral blood mononuclear cells (hPBMCs). Collectively, we proposed that entecavir and imipenem might be candidates for the treatment of CSS.
has issue date	2020-08-23(xsd:dateTime)
bibo:doi	10.1016/j.biopha.2020.110643
bibo:pmid	32846329
has license	no-cc
sha1sum (hex)	b39e6a6b85c80942eed6408290eac2319aede7e2
schema:url	https://doi.org/10.1016/j.biopha.2020.110643
resource representing a document's title	Drug repurposing of anti-infective clinical drugs: Discovery of two potential anti-cytokine storm agents
has PubMed Central identifier	PMC7443334
has PubMed identifier	32846329
schema:publication	Biomed Pharmacother
resource representing a document's body	covid:b39e6a6b85c80942eed6408290eac2319aede7e2#body_text
is schema:about of	named entity 'Syndrome' named entity 'addition' named entity 'Coronavirus' named entity 'Entecavir' named entity 'mice' named entity 'repurposing' named entity 'anti-infective' named entity 'SEVERELY' covid:arg/b39e6a6b85c80942eed6408290eac2319aede7e2 named entity 'identified' named entity 'infection' named entity 'SARS-CoV-2' named entity 'effective' named entity 'inhibited' named entity 'imipenem' named entity 'imipenem' named entity 'peripheral blood mononuclear cells' named entity 'NF-κB' named entity 'CSS' named entity 'CSS' named entity 'macrophage' named entity 'imipenem' named entity 'stained with haematoxylin and eosin' named entity 'exudates' named entity 'hyperinflammation' named entity 'saline' named entity 'serum' named entity 'IL-6' named entity 'CCK-8' named entity 'lipopolysaccharide' named entity 'entecavir' named entity 'cytokine storm' named entity 'lopinavir' named entity 'COVID-19' named entity 'entecavir' named entity 'CSS' named entity 'leukocytes' named entity 'entecavir' named entity 'mice' named entity 'antiviral' named entity 'TNF-α' named entity 'bronchoalveolar' named entity 'inflammation' named entity 'SARS' named entity 'infection' named entity 'histological' named entity 'TLR8' named entity 'Cell Signaling Technology' named entity 'macrophage inflammatory protein' named entity 'lung injury' named entity 'TNF-α' named entity 'supernatants' named entity 'antiviral' named entity 'Entecavir' named entity 'LPS' named entity 'Leica' named entity 'cytokines' named entity 'retrospective studies' named entity 'imipenem' named entity 'bovine serum albumin' named entity '0.01' named entity 'LPS' named entity 'BALF' named entity 'TNF-α' named entity 'cytokines' named entity 'COVID' named entity 'GM-CSF' named entity '1:500' named entity 'IL-6' named entity 'mice' named entity 'H&E' named entity 'entecavir' named entity 'p65' named entity 'TNF-α'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software